Lv5
930 积分 2024-09-30 加入
Efficacy and safety of atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis
1天前
已完结
Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study
1天前
已完结
Advances in Locoregional and Systemic Treatments for HCC
2天前
已完结
[Advancements and controversies in conversion therapy for biliary tract malignant tumors with insufficient future liver remnant]
13天前
已完结
Health and Economic Impact of Vein-to-Vein Time in CAR T-Cell Therapy in the Second-Line Treatment of Relapsed/Refractory Large B-cell Lymphoma: A US Cost-Effectiveness Analysis
19天前
已关闭
Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab–bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study
1个月前
已完结
Multidisciplinary Team Management of Hepatocellular Carcinoma Is Standard of Care
1个月前
已完结
Immune profiling of pancreatic cancer for radiotherapy with immunotherapy and targeted therapy: Biomarker analysis of a randomized phase 2 trial
1个月前
已完结
肝癌转化治疗中国专家共识（2021版）
1个月前
已完结
Hepatic arterial infusion of GEMOX plus systemic gemcitabine chemotherapy combined with lenvatinib and PD-1 inhibitor in large unresectable intrahepatic cholangiocarcinoma
1个月前
已完结
皖公网安备34019202002308
